8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                  _____________


                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15 (d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                          ____________________________


Date of report (Date of earliest event reported)   November 25 , 2002
                                                   ------------------


                              HELIX BIOMEDIX, INC.
- --------------------------------------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)



       Delaware                    33-20897-D                   91-2099117
- --------------------------------------------------------------------------------
(State or Other Jurisdiction       (Commission                  IRS Employer
    of Incorporation)              File Number)              Identification No.)



22122 20th Ave. SE #148, Bothell, WA                                    98021
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices)                              (Zip Code)



Registrant's telephone number, including area code   (425) 402-8400
                                                     ---------------




Item 4.  Changes in Registrant's Certifying Accountant

On November 25, 2002,  Helix BioMedix,  Inc. ("the Company") was informed by its
independent  auditors,  Comiskey  & Company,  P.C.,  that it would not stand for
reappointment  due to the current AICPA Public  Company  Practice  Section rules
requiring  audit  partner  rotation  every  seven  years.   Comiskey  &  Company
("Comiskey")  does not have an  additional  audit  partner  available to provide
audit services to the Company and  accordingly  Comiskey and Company will resign
as the Company's  independent  auditors effective for the December 31, 2002 Form
10-KSB.

The Company's Audit  Committee has selected KPMG as the new independent  auditor
for the Company.

During the  Company's two most recent  fiscal years and the  subsequent  interim
period through the date of this Report, there were no disagreements  between the
Company  and  Comiskey  on any matter of  accounting  principles  or  practices,
financial  statement   disclosure,   or  auditing  scope  or  procedure,   which
disagreements,  if not resolved to  Comiskey's  satisfaction,  would have caused
Comiskey  to  make  reference  to the  subject  matter  of the  disagreement  in
connection  with its reports;  and there were no reportable  events as listed in
Item 304 (a)(1)(v) of Regulation S-X.

Comiskey's audit reports on the Company's financial  statements for the past two
years did not contain any adverse  opinion or  disclaimer  of opinion,  nor were
they  qualified  or  modified  as to  uncertainty,  audit  scope  or  accounting
principles.  The  Company has  provided  Comiskey  with a copy of the  foregoing
disclosures.  A letter  from  Comiskey  is  attached  hereto  as  Exhibit  16.1,
indicating its concurrence with the disclosures provided.

Item 7. Financial Statements and Exhibits

     (c)  Exhibits

          16.1 Letter from  Comiskey and Company  regarding its  concurrence  or
               disagreement with the statements made in this report.

                                        2




                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                             HELIX BIOMEDIX, INC.


Date: November 27, 2002                      /s/  R. Stephen Beatty
      -----------------                      --------------------------------

                                             Name:    R. Stephen Beatty
                                             Title:   President and
                                                      Chief Executive Officer

                                        3

EX-16.1

EXHIBIT 16.1

                        LETTERHEAD OF COMISKEY & COMPANY





November 25, 2002




Securities and Exchange Commission
450 Fifth Street N.W.
Washington, D.C. 20549

Re:  Helix BioMedix, Inc.
       File No. 33-20897-D


Dear Sirs:

     We have read the  disclosures  made in Item 4 of the  report on Form 8-K of
Helix BioMedix,  Inc. (the "8-K Report") dated November 25, 2002, and agree with
the statements contained therein.


Very truly yours,


COMISKEY & COMPANY
PROFESSIONAL CORPORATION


By: /s/ Jennifer Maliar
    -------------------------
    Jennifer Maliar, C.P.A.